阿替普酶静脉溶栓联合脉血康胶囊治疗急性脑梗死患者的效果研究  

Effect of alteplase intravenous thrombolysis combined with Maixuekang capsules on patients with acute cerebral infarction

作　　者：于云霞[1] 高菊红[1] 邢玉波[1] 于元英[1] 姜树敏 Yu Yunxia;Gao Juhong;Xing Yubo;Yu Yuanying;Jiang Shumin(Department of Neurology, Haiyang People＇s Hospital, Haiyang 265100, China;Health Center of Panshidian Town of Haiyang City, Haiyang 265112, China)

机构地区：[1]海阳市人民医院神经内科,265100 [2]海阳市盘石店镇卫生院,265112

出　　处：《国际医药卫生导报》2018年第11期1685-1688,共4页International Medicine and Health Guidance News

摘　　要：目的探讨阿替普酶静脉溶栓联合脉血康胶囊对急性脑梗死（ACI）患者神经功能及血管内皮功能的影响。方法选取2014年8月至2017年9月本院92例ACI患者，按照随机数字表法分为观察组与对照组，各46例。常规治疗及干预基础上，对照组行阿替普酶静脉溶栓治疗，观察组行阿替普酶静脉溶栓＋脉血康胶囊治疗。对比两组治疗前后神经功能（NIHSS评分）、血管内皮功能[血清内皮素-1（ET—1）、一氧化氮（NO）]及凝血功能[凝血酶原时间（PT）、活化部分凝血活酶时间（APITT）、凝血酶时间（TT）、纤维蛋白原（FIB）]。结果治疗前两组NIHSS评分比较差异无统计学意义（P〉0．05），治疗后两组NIHSS评分较治疗前降低（P〈0．05），且观察组低于对照组[（8．73±2．06）比（14．85±3．11）,P〈0．05]；治疗前血清ET-1、NO水平比较差异无统计学意义（P〉0．05），治疗后两组血清ET-1、NO水平较治疗前改善（P〈0．05），且观察组血清ET—1水平低于对照组[（83．47±15．63）ng／ml比（90．25±16．78）ng／ml]，NO水平高于对照组[（124．69±15．81）μmol／L比（79．58±16．29）μmol／L]，两组比较差异均有统计学意义（均P〈0．05）；治疗前两组PT、APTT、TT、FIB比较差异无统计学意义（P〉0．05），治疗后两组盯、APTT、TT、FIB较治疗前改善（P〈0．05），且观察组PT、APTT、TT高于对照组，FIB水平低于对照组（均P〈0．05）。结论阿替普酶静脉溶栓联合脉血康胶囊治疗ACI疗效显著，可有效改善患者血管内皮功能及凝血功能，并促进神经功能恢复。Objective To investigate the effect of alteplase intravenous thrombolysis combined with Maixuekang capsules on the nerve function and vascular endothelial function in patients with acute cerebral infarction （ACI）. Methods A total of 92 cases of ACI patients in our hospital from August 2014 to September 2017 were selected and divided into the observation group and the control group according to the random number table, with 46 cases in each group. On the basis of the routine treatment and intervention, the control group was treated with alteplase intravenous thrombolysis, and the observation group was treated with alteplase intravenous thrombolysis and Maixuekang capsules. The nerve function （NIHSS score）, the vascular endothelial function [serum endothelin -1 （ET-I）, nitric oxide （NO）], and the coagulation function [prothrombin time （PT）, activated partial thromboplastin time （APTT）, thrombin time （TT）, fibrinogen （FIB）] before and after the treatment between the two groups were compared. Results There was no statistically significant difference in NIHSS score between the two groups before the treatment （P〉0.05）; after the treatment, the NIHSS scores of the two groups were lower than those before the treatment （P〈0.05）, and that of the observation group [（8.73±2.06） points] was lower than that of the control group [（14.85±3.11） points] （P〈0.05）. There were no statistically significant differences in the levels of serum ET-1 and NO before the treatment （P〉0.05）; after the treatment, the levels of serum ET-1 and NO were improved in the two groups （P〈0.05）, the level of serum ET-1 in the observation group [（83.47±15.63）ng/ml] was lower than that in the control group [（90.25±16.78） ng/ml], and the level of NO [（124.69±15.81） umol/L] was higher than that in the control group [（79.58±16.29） umol/L] （P〈0.05）. There were no statistically significant differences in PT, APTT, TT, and FIB between the two groups before the treat

关 键 词：急性脑梗死 阿替普酶静脉溶栓 脉血康胶囊 神经功能 血管内皮功能 

分 类 号：R743.33[医药卫生—神经病学与精神病学]